Lupin Limited has successfully concluded GST Department inspection and search proceedings at its registered office with no adverse findings reported. The pharmaceutical company informed stock exchanges about the completion of the inspection that was initiated on February 25, 2026, pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

GST Department Inspection Details

The inspection was conducted by the Assistant Commissioner of State Tax, Maharashtra under Section 67 of Maharashtra Goods & Service Tax Act, 2017. The proceedings were carried out at the company's registered office located at Kalpaturu Inspire, Off W. E. Highway, Santacruz (East), Mumbai.

Inspection Outcome and Company Response

The GST Department Maharashtra concluded their inspection and search proceedings on March 2, 2026 at 8:15 p.m. (IST). Lupin provided complete cooperation throughout the inspection period, furnishing all necessary information and documents as requested by the authorities. The company's disclosure confirms that no official communication regarding any adverse findings has been issued by the GST Department.

Financial Impact Assessment

According to Lupin's official disclosure to stock exchanges, the conclusion of the inspection and search proceedings has no impact on the company's financials. The inspection was characterized as routine proceedings focused on documentation related to GST compliance and input tax credit claims. The absence of adverse findings validates the company's tax compliance practices.

Regulatory Compliance and Disclosure

The disclosure was made to both the National Stock Exchange of India Limited and BSE Limited as mandated under SEBI Listing Regulations. Company Secretary and Compliance Officer Amit Kumar Gupta digitally signed the disclosure document on March 2, 2026, ensuring full regulatory compliance and transparency with stakeholders.

Lupin Limited has informed stock exchanges about a timeline extension for its subsidiary's acquisition of VISUfarma B.V., a Netherlands-based company. The pharmaceutical company communicated this update through a regulatory filing dated February 27, 2026.

Transaction Details

The acquisition involves Nanomi B.V., Lupin's wholly owned subsidiary in the Netherlands, acquiring the entire share capital of VISUfarma B.V. The company had previously communicated about this transaction through intimations dated September 29, 2025 and December 30, 2025.

Timeline Extension and Pending Approvals

The transaction, which was originally expected to be completed by February 28, 2026, is now anticipated to be completed in April 2026. The extension is attributed to the pending satisfaction of specific closing conditions that are required for the transaction completion. The deal delay reflects the complex nature of cross-border acquisitions where regulatory approvals and other conditions precedent need to be satisfied before transaction closure.

Regulatory Compliance

The update was communicated to both the National Stock Exchange of India Limited and BSE Limited under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was signed by Amit Kumar Gupta, Company Secretary & Compliance Officer of Lupin Limited.

The company stated that the proposed transaction is still ongoing and emphasized that the completion remains subject to fulfillment of specified closing conditions. This represents a standard approach in cross-border acquisitions where regulatory approvals and other conditions precedent need to be satisfied before transaction closure.